BEKINDA® (GI)
BEKINDA® (RHB-102) is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the antiemetic drug ondansetron, targeting multiple gastrointestinal indications.
Ondansetron is a 5-HT3 (serotonin) receptor antagonist which is marketed under various trade names including GSK’s Zofran®. 5-HT3 receptor antagonists are considered the most effective and significant class of drugs in prevention of nausea and vomiting.
BEKINDA® is currently the only once-daily oral formulation of ondansetron, and may be the first to reach the U.S. and European market.
BEKINDA® is being developed for several indications :
- Gastroenteritis and Gastritis: positive results from a Phase 3 clinical study in in the U.S.
- IBS-D (diarrhea-predominant irritable bowel syndrome): positive results from a Phase 2 clinical study in the U.S.
